Canberra. October 11, 2017
The Australian Influenza Vaccine Committee (AIVC) congregated at the Therapeutic Goods Administration (TGA) for the purpose of recommending influenza viruses to be used in the composition of the 2018 flu vaccine. The meeting involved review and evaluation of:
A side by side comparison to 2017 trivalent and quadrivalent vaccine compositions shows the difference in the introduction of a new A (H3N2) like virus constituent. For the Trivalent, the B/Brisbane strain swapped with the B/Phuket strain included in the Quadrivalent vaccine. The 2018 AIVC recommendations were accepted by the TGA.
Aitor is a Registered Nurse (AHPRA registration NMW0001159845) with over 17 years experience in General Nursing, Emergency Nursing and Corporate Health. He loves Flu, works with Flu, studies Flu, writes about Flu and ironically, he’s had the Flu.
He is the Nurse Consultant at Corporate Care and a proud member of the Australian National Padel Team.
Please complete the form below. One of our senior consultants will get back to you as quickly as possible. Our goal is to reply to every email within one business day.